Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

Marc A. Schneider; Thomas Muley; Nicolas C. Kahn; Arne Warth; Michael Thomas; Felix J.F. Herth; Hendrik Dienemann; Michael Meister

doi:10.18632/oncotarget.12474

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

Marc A. Schneider _, Thomas Muley, Nicolas C. Kahn, Arne Warth, Michael Thomas, Felix J.F. Herth, Hendrik Dienemann and Michael Meister

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:71285-71297. https://doi.org/10.18632/oncotarget.12474

Metrics: PDF 1577 views | HTML 2835 views | ?

Abstract

Marc A. Schneider1,6, Thomas Muley1,6, Nicolas C. Kahn1,4,6, Arne Warth2,6, Michael Thomas3,6, Felix J.F. Herth4,6, Hendrik Dienemann5,6 and Michael Meister1,6

1 Translational Research Unit, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

2 Institute of Pathology, University of Heidelberg, Heidelberg, Germany

3 Department of Thoracic Oncology, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

4 Department of Pneumology and Critical Care Medicine, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

5 Department of Surgery, Thoraxklinik at University Hospital Heidelberg, Roentgenstraße, Heidelberg, Germany

6 Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany

Correspondence to:

Marc A. Schneider, email:

Keywords: MPM, glycodelin, SMRP, biomarker, follow-up

Received: September 18, 2016 Accepted: September 25, 2016 Published: October 04, 2016

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a short survival time arising from the mesothelial cells of the pleura. Soluble mesothelin-related peptide (SMRP), osteopontin or EFEMP1 (Fibulin-3) are well described biomarkers for malignant mesothelioma with moderate sensitivity and specificity. In this study, we characterized the expression of glycodelin, a marker for risk pregnancy, in MPM by RNA and protein analyses and investigated its potential as a MPM biomarker. We were able to detect glycodelin in the serum of MPM patients. Compared to benign lung diseases, the serum levels were significant increased. Patients with high glycodelin serum levels revealed a worse overall survival. The glycodelin serum levels correlated with the tumor response to treatment. A comparison of SMRP and glycodelin serum measurement in a large patient cohort demonstrated that the detection of both soluble factors can increase the reliable diagnostic of MPM. Glycodelin was highly expressed in MPM tumors. Analyses of a tissue micro array indicated that the immunomodulatory form glycodelin A was expressed in MPM and correlated with the survival of the patients. Altogether, glycodelin seems to be a new potential biomarker for the aggressive malignant pleural mesothelioma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12474

Publication Alerts

Research Papers:

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

Abstract